CELC Stock Jumps As VIKTORIA-1 Data Fuel FDA Push

Celcuity Inc. stocks have been trading up by 15.38 percent after positive trial news boosted investor confidence.

Live Update At 16:02:20 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 15.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELC has turned into a momentum story, and the chart reflects it. Over the last few weeks, Celcuity Inc. has climbed from closes near $117–$120 up to $144.98 on 2026/05/04. That is a sharp multi-day uptrend, driven by traders reacting to the Phase 3 headlines and the bullish Wall Street coverage.

Intraday action on 2026/05/04 shows CELC opening around $141 and grinding higher into the mid-$140s, with several tight five-minute candles between $144 and $146. For short-term traders, that kind of controlled range after a big news move often signals strong hands holding and weak hands already shaken out.

More Breaking News

• NVTS Stock Pulls Back As Traders Digest Steep Run
• RIVN Stock Slips As Loan Cut, Tornado Damage Hit Outlook
• NBIS Stock Climbs As Nebius Lands TD SYNNEX AI Deal
• Celcuity CELC Soars On Strong Phase 3 Cancer Data

Fundamentally, Celcuity Inc. is still a development-stage biotech. The latest quarterly report shows net income of about -$50M and negative operating cash flow of roughly -$36M, classic for a late-stage clinical name. CELC holds about $165.7M in cash and $441.5M in cash plus short-term investments, paired with long-term debt of roughly $322M. A current ratio above 10 suggests CELC has runway to push gedatolisib through the upcoming regulatory catalysts, but the negative returns on equity underline that the story is all about future approvals, not current profits.

Why Traders Are Watching CELC Now

CELC is on a lot of trading screens because the science just lined up with the story. Celcuity Inc. reported that its Phase 3 VIKTORIA-1 trial in PIK3CA-mutant HR+/HER2- metastatic breast cancer hit its primary endpoint. Gedatolisib, combined with fulvestrant and sometimes palbociclib, beat alpelisib plus fulvestrant on progression-free survival with statistically significant and clinically meaningful benefit, and the safety profile stayed generally manageable.

For biotech traders, that kind of Phase 3 win is a major de-risking event. It moves gedatolisib from “high potential” to “commercially credible.” CELC amplified that momentum by confirming plans to submit a supplemental NDA to the FDA and other regulators based on these data, signaling a clear and near-term regulatory path.

The story does not stop with the mutant cohort. Celcuity Inc. already posted positive VIKTORIA-1 results in the PIK3CA wild-type population, and the new mutant data sit on top of that. Together, they support broad second-line use in HR+/HER2- advanced breast cancer, making gedatolisib look more like a platform therapy than a niche product.

Traders also pay attention when the Street steps in. Citizens initiated coverage of CELC with an Outperform rating and a $150 price target, explicitly tying that view to gedatolisib’s potential, the fresh VIKTORIA-1 results in PIK3CA-mutant patients, and the likely first approval in July for the wild-type setting. With a Priority Review already in place and a 2026/07/17 PDUFA date locked in, CELC now has a stacked catalyst calendar that momentum traders can plan around.

Conclusion

CELC is a classic high-risk, high-reward biotech setup, but with far more data under it today than just a few months ago. Celcuity Inc. has Phase 3 VIKTORIA-1 success in both PIK3CA-mutant and wild-type HR+/HER2- advanced breast cancer, a manageable safety profile, and a clear intent to file a supplemental NDA off the new results. Add the existing Priority Review and the 2026/07/17 PDUFA date, and CELC’s next 12–18 months are mapped out with real binary events.

At the same time, the financials remind traders what they are dealing with. CELC is burning cash, running negative earnings, and carrying notable long-term debt, while the share price already bakes in a lot of future hope. That is exactly why active traders focus on price action and catalysts, not stories alone. For those worried they’ve already “missed the move,” it’s worth remembering that setups in this name will likely come in waves around each catalyst. As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” That mindset helps traders stay patient and avoid forcing entries just because a chart has already run.

The recent Outperform initiation and $150 price target give another layer of validation to the gedatolisib thesis, but the market will ultimately react to each data drop and each FDA step. In the words of Tim Sykes, “The market doesn’t care about your opinion, only the price action — react to what’s happening, not what you wish would happen.” For CELC, that means respecting the uptrend, watching volume around every regulatory headline, and staying disciplined with risk while the catalyst machine runs.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.